Dr. Abajas is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
170 Manning Dr
# Cb
Chapel Hill, NC 27514Phone+1 919-966-1178Fax+1 919-843-6949
Education & Training
University of North Carolina HospitalsFellowship, Pediatric Hematology/Oncology, 2012 - 2015
University of Miami/Jackson Health SystemResidency, Pediatrics, 2009 - 2012
University of Miami Leonard M. Miller School of MedicineClass of 2009
Certifications & Licensure
NC State Medical License 2012 - 2025- American Board of Pediatrics Pediatrics
- American Board of Pediatrics Pediatric Hematology-Oncology
Clinical Trials
- Emicizumab PUPs and Nuwiq ITI Study Start of enrollment: 2022 Feb 17
Roles: Principal Investigator
Publications & Presentations
PubMed
- Bleed treatment with eptacog beta (rFVIIa) results in a low incidence of rebleeding in adult and adolescent patients with haemophilia A or B with inhibitors.Amy Dunn, Yesim Dargaud, Yasmina Abajas, Manuel Carcao, Giancarlo Castaman
Haemophilia. 2025-01-01 - Real-world effectiveness of eptacog beta in patients with haemophilia and inhibitors: A multi-institutional case series.Kimberley Youkhana, Glaivy Batsuli, Suchitra Acharya, Osman Khan, Duc Q Tran
Haemophilia. 2024-11-01 - 6 citationsCurrent practices in pediatric hospital-acquired thromboembolism: Survey of the Children's Hospital Acquired Thrombosis (CHAT) Consortium.Christina M Abrams, Julie Jaffray, Amy Stillings, Brian R Branchford, Guy Young
Research and Practice in Thrombosis and Haemostasis. 2022-10-01
Lectures
- Recombinant Porcine Factor VIII Use in Bleed Treatment in Non-Severe Hemophilia a Inhibitor Patients: Dosing Strategies and Efficacy2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Immune Tolerance Induction for FIX Inhibitors Using Combined B and T Cell Immune Modulation Therapy in Severe Hemophilia B2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
